Amino acid transporters are involved in functions reportedly linked to the sleep/wake cycle: neurotransmitter synthesis and recycling, the regulation of synaptic strength, protein synthesis, and energy metabolism. In addition, the existence of bidirectional relationships among extracellular content, transport systems, and sleep/wake states is receiving emerging support. Nevertheless, the connection between amino acid transport and sleep/wake regulation remains elusive. To address this question, we used Drosophila melanogaster and investigated the role of LAT1 (large neutral amino acid transporter 1) transporters. We show that the two Drosophila LAT1-like transporters: Juvenile hormone Inducible-21 and minidiscs (Mnd) are required in dopaminergic neurons for sleep/wake regulation. Down-regulating either gene in dopaminergic neurons resulted in higher daily sleep and longer sleep bout duration during the night, suggesting a defect in dopaminergic transmission. Since LAT1 transporters can mediate in mammals the uptake of L-DOPA, a precursor of dopamine, we assessed amino acid transport efficiency by L-DOPA feeding. We find that downregulation of JhI-21, but not Mnd, reduced the sensitivity to L-DOPA as measured by sleep loss. JhI-21 downregulation also attenuated the sleep loss induced by continuous activation of dopaminergic neurons. Since LAT1 transporters are known to regulate target of rapamycin (TOR) signaling, we investigated the role of this amino acid sensing pathway in dopaminergic neurons. Consistently, we report that TOR activity in dopaminergic neurons modulates sleep/wake states. Altogether, this study provides evidence that LAT1-mediated amino acid transport in dopaminergic neurons is playing a significant role in sleep/wake regulation and is providing several entry points to elucidate the role of nutrients such as amino acids in sleep/wake regulation.
Introduction
Emerging evidence suggests bidirectional relationships between extracellular space content and vigilance states [1] [2] [3] , emphasizing the so far little explored sleep-regulatory role of the transmembrane transport of ions and small molecules. Sleep and wakefulness have a pervasive impact on brain cellular activities linked to neurotransmission, neuronal plasticity, neurotransmitter synthesis, nutrient supply, and waste elimination, relying on the efficient and precise coordination of transport systems. Investigating how transporters and underlying molecular and cellular mechanisms are involved in these mutual interactions requires the targeting of individual genes in specific cell types. This strategy is highly amenable to the Drosophila model, which was spectacularly highlighted with the 2017 Nobel Prize awarded to J. C. Hall, M. Rosbash, and M. W. Young for their pioneer work on circadian-rhythm molecular mechanisms. Among the large array of cellular transporters present in the genome and conserved between insects and mammals, the well-characterized large neutral amino acid transporters are particularly relevant given their role in neurotransmitter synthesis and recycling, in the regulation of synaptic strength, in protein synthesis and energy metabolism [4] . In addition, the de novo synthesis of brain monoamines associated with wakefulness and neuromodulation, such as serotonin, dopamine, and noradrenaline, is dependent on large neutral essential amino acids provided by the blood.
The SLC7A5 (or large neutral amino-acid transporter, light chain or LAT1) and SLC7A8 (LAT2) amino acid transporters are present in most cell types and appear to play a prominent role in the Na + -independent transport of large branched and aromatic neutral amino acids. These transporters belong to the heterodimeric amino acid transporters (HAT) family [5] and require co-expression of the CD98hc /4F2hc (SLC3A2) heavy chain [6] , to which they can be covalently linked by a di-sulfur bridge. The heavy subunit does not appear to confer transport-specific properties, nor to be confined to HAT transporter function [6] . In the mammalian brain, LAT1 is highly expressed in the cells of the blood-brain-barrier [7] and is thought to play a critical role in providing the central nervous system with essential amino acids such as phenylalanine, tyrosine, leucine, and tryptophan, which are nutrients and precursors for monoamine synthesis [8] . The uptake of leucine through LAT1 is a major activator signal for target of rapamycin complex 1 (TORC1), a cellular pathway dependent on the TOR kinase [9] that controls protein synthesis, brain excitability, and plasticity [10] . Reciprocally, inhibition of mTOR by rapamycin has been shown to significantly reduce the activity and the mRNA expression of LAT1 [11, 12] . Despite a few pieces of evidence [13, 14] , it remains to be investigated whether LAT1, LAT2, or other SLC7A transporters are also localized in neurons, and whether their function is linked to sleep and wake. In Drosophila, the HAT family of transporters is represented by one heavy chain, CD98hc, and five light chains: juvenile hormone inducible-21 (JHI-21), minidiscs (MND), genderblind (GB), CG9413 protein, and CG1607 protein [4] . The specific activity of these transporters cannot be easily predicted from their sequences and requires functional testing. JHI-21 and MND can transport leucine, are inhibited by BCH (2-aminobicyclo[2.2.1]heptane-2-carboxylic acid), and, at least for JHI-21, require CD98hc to become functional [15] , thus classifying them as LAT1-LAT2 homologs. Both genes are expressed at high levels in the central nervous system and have been shown to play important neurophysiological functions. JHI-21 and GB regulate glutamatergic synaptic strength, primarily through the regulation of extracellular glutamate levels, and are, respectively, required in motor neurons and in glial cells [16] [17] [18] . In a recent report, we have also shown that MND is required to activate brain insulin-producing neurons in response to circulating leucine [19] . Interestingly those same insulin-producing neurons are connected to wakefulness promoting circuits [20] . In the present study, we used the molecular-genetic tools of Drosophila to investigate the potential impact of JhI-21 and Mnd downregulation in neuronal subsets on sleep/wake regulation.
Methods

Fly stocks and husbandry
Flies were reared at 25°C, 50%-60% humidity, in a 12 hr light/ dark cycle using standard food containing inactivated yeast, molasses, sucrose, and agar. The following stocks obtained from the Bloomington Drosophila Stock Center (NIH P40OD018537) were used in this study:
UAS-TOR-RNAi
HMS00904
, and UAS-mCD8-GFP (referred in text as Figure S1 ). For the experiments using the TARGET system [21] or UAS-TrpA1, flies were raised at 18°C and their sleep was first recorded at 18°C for 2 days, before being shifted to 30°C for 3 days. Data shown correspond to day 2 at each temperature.
UAS-GFP). UAS-JhI
Sleep monitoring
Freshly hatched females were collected from culture vials under CO 2 anesthesia and transferred individually to 5 × 65 mm glass tubes at 2-5 days of age for continuous sleep recordings. Sleep parameters were evaluated across 3-5 days of baseline as described previously using 5 min immobility as criteria [22] [23] [24] . Trikinetiks locomotor activity monitors (www.trikinetics.com) and the Drosophila ARousal Tracking (DART) system [25] were used to track fly movements. At least 32 flies from two separate experiments were tested for each condition. Distribution and homogeneity as well as statistical group comparisons were tested using Microsoft Excel plugin software Statel. KruskalWallis test or ANOVA was used in multigroup comparison followed by post hoc tests. The p value shown is the highest obtained among post hoc comparisons. Except otherwise mentioned, mean ± SEM is plotted.
Immunohistology
Primary antibodies were rabbit anti-MND (1/250), rabbit anti-JHI-21 (1/250), and mouse anti-GFP (1/200, Sigma #G6539) [16, 19, 26] . Secondary antibodies (anti-rabbit IgG-Alexa Fluor 594 and anti-mouse IgG-Alexa Fluor 488) were purchased from Thermo Fisher Scientific and used at 1/400. Whole-mount adult brains were dissected in PBS and fixed in 4% paraformaldehyde for 45 min at room temperature (RT). The tissues were washed 6 × 10 min in PBS + 0.3 Triton X-100 (PBS-T) and 1 × 10 min in PBS + 1% Triton X-100. Brains were blocked in PBS-T, supplemented with 10% normal goat serum (NGS; Sigma #G9023) for 1 hr at RT and then incubated with antibodies diluted in PBS-T + 5% NGS overnight at 4°C. After washing 6 × 10 min in PBS-T, samples were labeled with the appropriate secondary antibodies at 1:400 in PBS-T + 5% NGS for 3 hr at RT. They were washed for 6 × 10 min in PBS and mounted in Vectashield mounting medium (Vector Laboratories). Fluorescence was observed using a confocal microscope (Leica TCS SP8).
Fluorescence quantification
The presence of GFP in TH-Gal4 > UAS-GFP flies was used to localize and identify the different clusters of dopaminergic neurons. Confocal images were obtained using 63× objective and performed every 0.5 µm in depth. Mean MND or JHI-21 immunofluorescence intensity in each dopaminergic neuron cluster of 10 brains was quantified from confocal z-stack maximal-projection images using FIJI software. The signal was also quantified in a chosen region adjacent to each cluster and used to normalize the immunofluorescence data across brains. Control genotype (TH-Gal4 > UAS-GFP) for all neuron clusters served as a reference (immunofluorescence = 1). The same laser power and scanning settings were used for all samples. All data were transferred to Prism6 software (Graphpad) for statistical analysis and tested for normal distribution using d'Agostino and Pearson omnibus normality test. Normally distributed data were compared using the Student's unpaired t-test. Data sets that did not pass the normally test were analyzed using the Mann-Whitney test.
L-DOPA (L-3,4-dihydroxyphenylalanine) feeding
Flies in Trikinetics tubes were transferred at ZT0 from standard food to vehicle (1% agar 1% sucrose) for 24 hr (day 1). At ZT0 the following day, flies of each genotype were divided into two groups, one placed on fresh vehicle for 24 hr (food change condition) and the other one on vehicle plus L-DOPA dissolved at 3 mg/mL (day 2). The percentage of nighttime sleep change was calculated and displayed in the figure: (day2 sleep − day1 sleep)/ day1 sleep.
Analysis of single brain dopamine content using high performance liquid chromatography
Flies were individually cold-anesthetized and quickly dissected in ringer solution. Each brain was immediately frozen in 1μL of ringer solution in dry ice and kept at -80°C until being processed for high performance liquid chromatography (HPLC). For monoamine extraction, 3 µL of ice-cold 0.1 mol/L perchloric acid containing 1.34 mmol/L EDTA and 0.05%, w/v sodium bisulfite were added and samples were sonicated in an ultra-sonic bath for 12 min. The homogenates were centrifuged at 15,000 × g for 20 min at +4°C, and the supernatants analyzed for monoamine content on the same day or the following day in case of unsuccessful injection in HPLC system.
The HPLC system consisted of a Prominence degasser, an LC-30 AD pump, and an SIL-30AC autosampler from Shimadzu. Detection was carried out at 30°C using a Decade II electrochemical detector fitted with a 2 mm glass carbon working electrode, an Ag/AgCl reference electrode, and an adaptable spacer adjusted to position 0.5 (Sencell, Antec). Separations were performed in the detector oven at 30°C using a capillary 150 × 0.5 mm Zorbax-SB C18 5 µm column. The mobile phase, which was pumped at a flow rate of 8 µL/min, consisted of 100 mmol/L sodium phosphate containing 0.1 mmol/L EDTA, 2 mmol/L octane sulfonate, and 0.01% triethylamine, with a pH adjusted to 5.5 with sodium hydroxide, filtered through a 0.22 µm membrane before use and mixed with 17% methanol (V:V). Analytes were detected at an oxidation potential of 700 mV versus the reference electrode. Chromatograms were acquired at a rate of 10 Hz using Lab Solutions software. The acquisition time was 25 min per sample. The injection volume was 0.1 µL. Concentrations of dopamine and serotonin in the extracts were determined by comparison of chromatographic peak areas with calibration curves derived from a mixture of synthetic standards containing dopamine and serotonin (two points: 10 
Assessment of food intake
Food intake was evaluated using the CAFE assay [27] : briefly, we used for these experiments vials containing five flies each, and food was provided by a 5 μL-calibrated capillary filled with liquid food containing 5% of sucrose, 5% of extract of yeast, 1% of blue food-coloring die, and L-DOPA (3 mg/mL). Experimental readings and capillaries replacement were carried out every 12 hr. Each experiment included an identical CAFE chamber without flies to determine evaporative losses (typically <10% of ingested volumes), which were subtracted from experimental readings.
Results
Downregulation of Mnd and JhI-21 in dopaminergic neurons increases sleep
To investigate the role of the neuronal expression of Mnd and JhI-21 in sleep/wake regulation, we used the Gal4-UAS system with UAS-RNAi constructs to downregulate Mnd and JhI-21 in a tissue-specific manner. Given the reported role of amino acid transporters in regulating neurotransmitter levels, neuronal subtypes releasing one particular neurotransmitter were targeted using different Gal4 driver lines: dopamine (TH-Gal4), serotonin (TpH-Gal4), octopamine (Tdc2-Gal4), GABA (vGat-Gal4), glutamate (vGlut-Gal4), or insulin-like peptide 2 (Ilp2-Gal4).
Targeting Mnd or JhI-21 in serotoninergic, glutamatergic, octopaminergic, or insulinergic neurons had no effect on total daily sleep compared with controls ( Figure 1) . A closer examination of this particular phenotype showed similar features in both transporter knockdowns (Figure 1 ). The increase in sleep was mostly due to longer sleep bout duration, on average three times longer than controls, during nighttime. Bout number was reduced during the night, but not sufficiently to achieve normal sleep quotas (Figure 1, A-C) . Latency between lights off and the first bout of sleep was also shorter compared with both controls, contributing to higher night sleep amounts (Supplementary Figure S3) . Sensory threshold during the night was similar between control flies and transporter knockdown flies, suggesting that sleep depth was not lighter in those flies. Similarly, preferential location close to food during sleep was unaffected (Supplementary Figure S3) . Downregulation of either JhI-21 or Mnd did reduce total locomotor activity due to extended sleep quotas but did not reduce the intensity of locomotor activity during waking as assessed using the infrared beam system or video tracking (Supplementary Figure S3) . We further temporally restricted the induction of the UAS-RNAi constructs using the TARGET system ( Figure 2 ) [21] . In this system, GAL80 ts protein expression is under the control of the pancellular tubulin promoter. At nonpermissive temperature (18°C), the GAl80 ts protein interacts with and blocks GAL4 activity. At permissive temperature (30°C), Gal80 ts protein is inactivated, allowing GAL4 to induce the expression of the UAS-RNAi [21] . As shown in Figure 2 , restricting the expression of the UAS-RNAi to the adult stage resulted in an increase of daily sleep amounts, including a longer average sleep bout duration at night (Figure 2 Given that dopaminergic transmission plays a major role in Drosophila wakefulness, these results suggest that both JhI-21 and Mnd are required to maintain a proper level of activity in dopaminergic neurons.
MND and JHI-21 are present in dopaminergic neurons
Mnd and JhI-21 have previously been reported to be expressed in the brain [16, 19, 26, 28, 29] ; however, their specific expression in dopaminergic neurons had not been previously assessed. Using previously validated antibodies, we confirmed that MND and JHI-21 are expressed in the brain and in dopaminergic neurons labeled by the TH-Gal4 driver (Figure 3 ) [16, 19, 26] . The expression of both transporters is broadly distributed in the brain and relatively uniform among dopaminergic neuronal subsets, but the effect of UAS-RNAi expression was unequal. In TH-Gal4 > UAS-Mnd-RNAi brains, MND immunofluorescence intensity dropped in PPL1, PPL2ab, PPL2c, and PPL3 clusters but not in other TH-Gal4 positive neurons (Supplementary Figure S6A) . In TH-Gal4 > UAS-JhI-21-RNAi brains, JHI-21 immunofluorescence intensity decreased in the majority of the clusters (PPL1, PPL2ab, PPL2c, PPL3, PPM2, PAL, and PAM) (Supplementary Figure S6B) . Importantly, we did not detect an increase in expression in one transporter compensating the knockdown of the other (Supplementary Figure S7) . These quantifications were based on the signal intensity observed in clearly identified cell bodies, which may not be representative of expression in dendrites and synaptic terminals, and could be potentially underestimated.
No obvious morphological defects were observed in the dopaminergic neurons expressing TH-Gal4, including the PPL2ab, in which the expression of the transporters was the most strongly reduced. Expressing JhI-21 and Mnd UAS-RNAi constructs in restricted subsets of dopaminergic neurons, including those involved in sleep/wake regulation, such as PPL1 (TH-D1-Gal4, TH-D'-Gal4, MZ840-Gal4), PPM3 (TH-D'-Gal4, TH-C'-Gal4), or PAM (NP-6510-Gal4, GMR58E02-Gal4) did not produce abnormal phenotypes [30, 31, 32] .
JhI-21 acts on dopaminergic neurons to modulate sensitivity to L-DOPA
Since our gene manipulation and expression data indicated that MND and JHI-21 in dopaminergic neurons are required for sleep/wake regulation, we next attempted to determine the function fulfilled by these transporters. It has been reported that LAT1 transporters can mediate the uptake of the amino acid L-DOPA in mammals [14] . In dopaminergic neurons, L-DOPA is converted to dopamine, and feeding flies with food containing L-DOPA results in a reduction of nighttime sleep, as well as an increase in global brain dopamine content as measured with HPLC ( Figure 4A ) [33] [34] [35] . We used L-DOPA feeding as an indirect assay to assess LAT1-like transport function in dopaminergic neurons. Knockdown of Mnd in dopaminergic neurons did not affect the sensitivity to L-DOPA as measured using sleep loss ( Figure 4B ). In contrast, knockdown of JhI-21 significantly attenuated L-DOPA-induced sleep loss ( Figure 4D , Supplementary Figure S5 , C and D). These phenotypes were not confounded by food intake, which was similar in all genotypes ( Figure 4 , C and E). To determine whether the reduced sensitivity to L-DOPA observed in JhI-21 knockdown flies is a consequence of insufficient dopamine synthesis, we measured global brain dopamine content using HPLC [33] [34] [35] . Baseline dopamine levels were similar in all genotypes, suggesting that baseline dopamine synthesis is unaffected by JhI-21 knockdown ( Figure 4F ). As expected, the presence of L-DOPA in the food increased the quantity of dopamine measured in control flies (TH-Gal4/+ or UAS-JhI-21-RNAi/+, Figure 4F) . Surprisingly, JhI-21 downregulation was not associated with a less increase in brain dopamine synthesis in response to L-DOPA feeding. These results suggest that JhI-21 knockdown was not sufficient to affect global dopamine levels and raise the possibility that this transporter is involved in other aspects of dopaminergic neuron physiology.
JhI-21 function affects dopaminergic neuron physiology
Since JhI-21 knockdown produced a severe sleep phenotype and affected L-DOPA sensitivity, we focused our analysis only on this gene. To evaluate the requirements of transporter expression for dopaminergic activity, we acutely increased dopaminergic neurons activity using the heat-activated channel TrpA1 while downregulating JhI-21 expression. Downregulating JhI-21 significantly reduced the insomnia resulting from dopaminergic neurons hyperactivity, suggesting that the transporter is required to sustain the metabolic demand of high neuronal activity ( Figure 5A , Supplementary Figures S4C and S5 , E and F). To further test this hypothesis, we combined JhI-21 downregulation in dopaminergic neurons with the DAT fumin mutation. DAT encodes the Drosophila dopamine transporter (DAT), which is involved in the reuptake of dopamine at the synapse [36] . Thus, DAT fumin mutants presumably rely predominantly on de novo dopamine synthesis as shown in DAT knock-out mice [37] . The reduced reuptake in DAT fumin mutants results in dopamine receptor hyperactivation and insomnia ( Figure 5D ) [36, 38] . 
TOR activity in dopaminergic neurons modulates sleep/wake states
LAT1 activity has been shown to be required to activate the TOR amino acids sensing pathway, and the TOR pathway can itself regulate neuronal excitability. Thus, we evaluated whether a down-regulation of this pathway could replicate JhI-21/Mnd downregulation. As shown in Figure 6 , A and B, the expression of a UAS-TOR-RNAi in dopaminergic neurons resulted in an increase in sleep throughout the day, whereas similar levels of locomotor activity were observed in all genotypes (Supplementary Figure S8) . Bout duration was only increased during the day in this condition, with a trend for a higher number of night sleep bouts ( Figure 6C ). As in JhI-21/Mnd downregulation, latency was shortened (Supplementary Figure S8) . 
Discussion
This study provides evidence that the LAT-1 like transporters JhI-21 and Mnd are required in adult fly dopaminergic neurons to achieve adequate sleep/wake regulation. Our results demonstrate that a downregulation of these transporters in dopaminergic neurons results in a decrease in wakefulness, under baseline conditions but also in conditions that increase dopaminergic transmission. This implies that the activity of dopaminergic neurons and/or their ability to release neurotransmitter requires JhI-21 and Mnd. These two amino acid transporters are the closest drosophila LAT1 homologs based on sequence and functional data [15] , suggesting that some amino acid availability plays a critical role in dopaminergic neuronal function. Supporting this hypothesis, we find that downregulating the TOR pathway in dopaminergic neurons results in a decrease in wakefulness. As in mammals, dopaminergic transmission plays a major role in Drosophila wakefulness [39] and has been suggested to constitute a core ancestral regulator of arousal and sleep entry across invertebrates [40] . Drosophila and mammals share homologs for genes playing a central role in dopamine synthesis, reuptake, and signaling. This includes two D1-like receptors and one D2-like dopamine receptor. Among those, the D1-like receptor Dop1R1 (dDA1) plays a prominent role in sleep/wake regulation. Dop1R1 mutant flies display high daily sleep, longer sleep bout duration, and normal waking activity, a phenotype that closely resembles the one obtained here by downregulating JhI-21 or Mnd in dopaminergic neurons [41] . The effect of Dop1R1 on sleep/wake depends on its expression in the dorsal fan-shaped body (dFB), a key sleep-wake regulatory structure, and on the release of dopamine by a very limited set of dopaminergic neurons projecting to the dFB and located in the PPL1 and PPM3 cluster [30, 41] . Thus, it is possible that Mnd and JhI-21 are required in those specific neurons to achieve normal sleepwake regulation. Expressing Mnd and JhI-21 UAS-RNAi constructs in PPL1 and PPM3 neurons failed to produce an abnormal sleep/wake phenotype. This lack of effect may be attributable to the limited efficiency of the UAS-RNAi constructs. Alternatively, the inhibition of JhI-21 and Mnd may affect multiple dopamine dependent microcircuits throughout the brain and thus cannot be easily replicated by a more specific manipulation.
What function could JHI-21 and MND fulfill in dopaminergic neurons? At the glutamatergic neuromuscular junction, JHI-21 appears to regulate the clustering of post-synaptic glutamate receptors [16] . JHI-21 does not appear to trigger directly the release of glutamate in this context, but possibly mediates the entry of amino acids such as leucine to activate molecular pathways controlling glutamatergic physiology [16] . Although we did not observe an abnormal sleep/wake regulation when JhI-21 was inhibited in glutamatergic neurons (Table 1) , our results indicate that JhI-21 could play a role in dopaminergic physiology similar to the one hypothesized for the neuromuscular junction. The synthesis of brain monoamines depends on the supply of essential amino acids that are provided by food intake, thus requiring efficient cellular transport systems. Although we show here that dopaminergic neuron function is impaired when JhI-21 expression is downregulated, we found no evidence of reduced brain dopamine levels under baseline conditions. Dopamine levels were increased in the mutant flies fed with the dopamine precursor L-DOPA, an amino acid that has been shown to be transported by LAT1 [14] , further suggesting that JhI-21 expression is not critical for dopamine synthesis. In this experiment, dopamine synthesis could also take place ectopically in dopa-decarboxylase (ddc) expressing serotoninergic neurons, in which the UAS-JhI-21-RNAi construct was not expressed. Dopamine content was still increased, although moderately, in flies in which the UAS-JhI-21-RNAi construct was targeted to both dopaminergic and serotoninergic neurons using the ddc-Gal4 driver (Supplementary Figure S9) . The lack of impact of JhI21 downregulation on L-DOPA-induced increase in dopamine synthesis could be due to functional redundancy between JhI-21 and Mnd, or could be a consequence of the partial inhibition provided by the UAS-RNAi constructs. In contrast to those findings on tissue content, we clearly observed that JhI-21 downregulation in dopaminergic neurons reduced the sensitivity to L-DOPA as measured with sleep loss, and significantly attenuated the sleep loss phenotype of the TH-GaL4 > UAS-TrpA1 hyperdopaminergic condition. This raises the possibility that JhI-21 mediates the entry of amino acids critical for the physiology of dopaminergic neurons, such as leucine that could activate TOR-dependent processes influencing protein synthesis and energy metabolism, but is not directly involved in dopamine synthesis through the transport of precursors such as tyrosine or phenylalanine (Supplementary Figure S10) . The phenotype observed in flies where both Rheb and JhI-21 are manipulated indicates that JhI-21 could be required for TOR pathway activation. This hypothetical model is conceivable since in mammals enriched intracellular leucine levels via LAT1 transport activate mTORC1 [9, [42] [43] [44] . Alternatively, TOR signaling could modulate JHI-21 function and affect LAT1-like-dependent transport mechanisms required for neuronal activity [45] . Elucidating the relationships between TOR signaling and LAT1-like transporters, and understanding how they play a critical role in dopaminergic neurons function will require further work.
We show that the MND and JHI-21 transporters are broadly expressed in the brain. However, targeting the JhI-21 and Mnd UAS-RNAi constructs to most nondopaminergic cell types, including the wake-promoting octopaminergic neurons, failed to affect sleep-wake regulation. This lack of effect may be attributable to the efficiency of genetic tools or alternatively to the more stringent requirement for these transporters in dopaminergic neurons. Further studies are warranted to further evaluate this question. Interestingly, accumulating pieces of evidence support the existence of a dynamic regulation for JhI-21 and Mnd: JhI-21 is modulated during larval development in close correlation with behavioral changes [16] , and in adult after longterm memory conditioning [46] , whereas Mnd is differentially expressed after sleep deprivation [47] . The expression of LAT1 transporters in mammalian dopaminergic neurons has not been investigated yet; however, a report using pharmacological methods suggested that such transporters could modulate neuronal activity [13] . The fact that sleep deprivation induces changes in TOR signaling in the brain opens the possibility that LAT1 could be modulated by sleep/wake in mammals [48] . Of note, sleep deprivation could induce changes in LAT1 expression at the blood-brain barrier [49] .
In conclusion, this study reveals the role of LAT1-like transporters in the function of dopaminergic neurons, adding one more element to the array of cellular and molecular events affecting sleep/wake regulation. Since these transporters are known to be dynamically regulated by physiological cellular states, they provide an entry point to elucidate the role of nutrient in sleep/wake regulation.
